Hye Sook Chon, MD
Gynecologic Oncology · Tampa, FLNPI 1619102563
Payments from drug & device makers
Across 330 payments — averaging $7265.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$918K
- AstraZeneca$717K
- Karyopharm Therapeutics Inc.$302K
- GSK$215K
- Ascendis Pharma Endocrinology Inc$188K
- Seagen Inc.$30K
- plus $27K from 8 others
What the payments were for
- Consulting fees$24,67585%
- Speaking & faculty fees$7503%
- Travel & lodging$1,8816%
- Food & beverage$1,5885%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 115 | $918,283 |
| AstraZeneca | 3 | $717,140 |
| Karyopharm Therapeutics Inc. | 136 | $301,570 |
| GSK | 20 | $215,357 |
| Ascendis Pharma Endocrinology Inc | 21 | $188,164 |
| Seagen Inc. | 2 | $30,015 |
| Eisai Inc. | 18 | $19,508 |
| Acrotech Biopharma Inc. | 5 | $5,864 |
| AbbVie | 2 | $720 |
| Verastem, Inc. | 1 | $360 |
| Foundation Medicine, Inc. | 2 | $269 |
| Tesaro, Inc. | 2 | $143 |
| Boston Scientific | 2 | $123 |
| Astellas Pharma Global Development | 1 | $99 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$19,229
- RYZNEUTA$5,864
- LYNPARZA$525
- FOUNDATIONONE$173
- FOUNDATIONONE CDX$173
- FOUNDATIONONE HEME$173
- FOUNDATIONONE LIQUID$173
- FOUNDATIONFOCUS$173
- Elahere$120
- ZEJULA$107
How this compares
$2,397,617 in reported general payments places this provider in the 90th percentile of 117 gynecologic oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Tampa
- Robert WenhamTampa$2.9M
- Vaagn AndikyanTampa$279K
- Mian ShahzadTampa$131K
- Jing-Yi ChernTampa$44K
- Thomas RutherfordTampa$6K
- Matthew SchlumbrechtMiami$16.7M
- Brian SlomovitzFort Lauderdale$13.9M
- Bradley MonkWest Palm Beach$10.5M
- John DiazMiami$3.7M
- Robert HollowayOrlando$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.